Syndax Pharmaceuticals (SNDX) Income towards Parent Company: 2015-2024
Historic Income towards Parent Company for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to -$318.5 million.
- Syndax Pharmaceuticals' Income towards Parent Company fell 39.81% to -$19.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$71.4 million, marking a year-over-year decrease of 24.13%. This contributed to the annual value of -$318.5 million for FY2024, which is 52.40% down from last year.
- Latest data reveals that Syndax Pharmaceuticals reported Income towards Parent Company of -$318.5 million as of FY2024, which was down 52.40% from -$209.0 million recorded in FY2023.
- Syndax Pharmaceuticals' 5-year Income towards Parent Company high stood at $24.7 million for FY2021, and its period low was -$318.5 million during FY2024.
- For the 3-year period, Syndax Pharmaceuticals' Income towards Parent Company averaged around -$225.5 million, with its median value being -$209.0 million (2023).
- As far as peak fluctuations go, Syndax Pharmaceuticals' Income towards Parent Company skyrocketed by 133.90% in 2021, and later tumbled by 702.74% in 2022.
- Over the past 5 years, Syndax Pharmaceuticals' Income towards Parent Company (Yearly) stood at -$72.9 million in 2020, then spiked by 133.90% to $24.7 million in 2021, then crashed by 702.74% to -$149.0 million in 2022, then plummeted by 40.25% to -$209.0 million in 2023, then slumped by 52.40% to -$318.5 million in 2024.